Država: Kanada
Jezik: angleščina
Source: Health Canada
BUDESONIDE
TILLOTTS PHARMA GMBH
A07EA06
BUDESONIDE
3MG
CAPSULE (SUSTAINED-RELEASE)
BUDESONIDE 3MG
ORAL
100
Prescription
ADRENALS
Active ingredient group (AIG) number: 0116807006; AHFS:
APPROVED
2000-02-08
_ _ _ _ _ENTOCORT_ _® _ _(Budesonide Controlled Ileal Release Capsules) _ _Page 1 of 31_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR ENTOCORT® Budesonide Controlled Ileal Release Capsules Capsule (sustained-release), 3 mg, Oral use Glucocorticosteroid Tillotts Pharma GmbH Warmbacher Strasse 80 79618 Rheinfelden Germany Date of Initial Authorization: AUG 15, 1996 Date of Revision: MAR 09, 2023 Importer/Distributor: C.R.I. Burlington, ON L7N 3G2 Submission Control Number: 268608 _ _ _ _ _ENTOCORT_ _® _ _(Budesonide Controlled Ileal Release Capsules) _ _Page 2 of 31_ RECENT MAJOR LABEL CHANGES WARNINGS AND PRECAUTIONS, Hypersensitivity 03/2023 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED . RECENT MAJOR LABEL CHANGES ........................................................................................... 2 TABLE OF CONTENTS ............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ..................................................................... 4 1 INDICATIONS .............................................................................................................. 4 1.1 Pediatrics ................................................................................................................... 4 1.2 Geriatrics ................................................................................................................... 4 2 CONTRAINDICATIONS ................................................................................................. 4 4 DOSAGE AND ADMINISTRATION ................................................................................. 4 4.1 Dosing Considerations .............................................................................................. 4 4.2 Recommended Dose and Dosage Adjustment ......................................................... 4 4.4 Administration ................................. Preberite celoten dokument